卵巢恶性肿瘤年轻患者保留生育功能手术的效果评价

目的总结评价卵巢恶性肿瘤年轻患者保留生育功能手术和术后辅助化疗的效果及对生育功能及卵巢功能的影响.方法回顾性分析四川大学华西第二医院1989-2004年收治的64例接受保留生育功能手术治疗的卵巢恶性肿瘤年轻患者的临床资料.结果初诊时患者中位年龄为20（7～30）岁.64例患者中,卵巢上皮性癌患者22例,恶性生殖细胞肿瘤38例,性索间质肿瘤4例.首次手术方式如下：单侧附件切除术23例;单侧附件切除＋大网膜切除＋阑尾切除术10例,单侧附件切除＋大网膜切除＋阑尾切除＋盆腔淋巴结切除或取样术10例;单侧附件切除＋肿瘤细胞减灭术4例;单侧附件切除＋对侧卵巢楔形切除活检术11例;6例仅行患侧肿瘤剥除术.64例患者平均随访76（5～192）个月,5例（8%）死亡,59例（92%）存活至今,其中卵巢恶性生殖细胞肿瘤患者存活率为89%（34/38）,上皮性癌患者为95%（21/22）,性索间质肿瘤患者全部健在（4/4）.15例患者行二次手术,其中发现癌灶者6例.生存病例中53例患者有月经,除2例周期缩短外,其余患者月经均正常.20例有生育计划的患者中,13例（65%）患者有15次妊娠,9次足月分娩.结论对卵巢恶性生殖细胞肿瘤患者,无论期别如何,行保留生育功能手术是可行的;对于卵巢上皮性癌患者行保留生育功能手术需慎重,仅限于年轻、有强烈生育要求、肿瘤为Ⅰ期、高分化且术后有条件密切随访的患者;坚持规范化疗对卵巢恶性肿瘤的治疗十分必要;化疗对卵巢及生育功能无明显影响.     

化疗对年轻卵巢恶性肿瘤患者保留生育功能手术后卵巢功能的影响

目的探讨保留生育功能手术的卵巢恶性肿瘤患者接受化疗对卵巢功能的影响。方法 1994年10月至2010年1月间保留生育功能手术的卵巢恶性肿瘤患者30例,分析化疗对其月经情况、性激素水平及生育情况的影响。并以同期因卵巢上皮交界性肿瘤行保留生育功能手术术后未接受化疗者28例为对照组。结果 30例保留生育功能手术后化疗的卵巢恶性肿瘤患者中,21例（70%）出现月经异常,其中12例（40%）发生停经,9例（30%）出现月经减少,停经出现在化疗后1～4个月[平均（2.17±0.8）个月]。发生停经的12例患者化疗结束后均恢复月经;月经恢复时间在化疗结束后2～7个月[平均（3.42±1.38）个月]。采用化疗方案为BEP方案（16例）、PVB方案（5例）、PT方案（3例）和PC方案（6例）,其发生停经的例数分别为6例、1例、0例和5例。对照组28例中,术后2例（7.14%）出现月经减少,均未出现停经。与化疗组比较,差异有统计学意义（P〈0.05）。化疗组5例停经患者停经期间黄体生成素和卵泡刺激素均明显升高,雌二醇明显降低。对照组6例术后血清性激素与术前比较,均无明显变化。化疗组30例患者中,12例有生育计划,其中4例已成功妊娠分娩;对照组14例有生育要求患者,8例成功妊娠分娩,子代均健康无畸形。化疗组中,2例死亡,28例无瘤生存;对照组全部无瘤生存。结论年轻妇女卵巢恶性肿瘤行保留生育功能的手术后化疗,可发生卵巢功能损害;其主要表现为停经或月经减少,血清促性腺激素水平升高,雌激素水平降低。化疗导致的停经是可逆的。化疗对患者的生育功能可能有一定影响,但对子代无明显致畸作用。     

卵巢恶性生殖细胞肿瘤保守治疗探讨

目的 探讨卵巢恶性生殖细胞肿瘤（MOGCT）保守治疗对患者存活率、月经和生育功能的影响.方法 1987年1月至2004年10月对天津医科大学总医院妇科共收治MOGCT患者50例中的22例行保守手术,21例行广泛性切除手术,7例行姑息手术,比较3种术式患者的存活率.行保守手术和辅助化疗并存活的MOGCT患者17例（研究组）,随机抽取同期因成熟型畸胎瘤行单侧附件切除术的未绝经患者35例（对照组）与之对照,比较两组治疗后的月经和生育功能.结果 MOGCT占卵巢恶性肿瘤的9.35%,广泛手术和保守手术的存活率分别为74.97%和43.85%（P＞0.05）;研究组和对照组月经紊乱的发生率分别为26.32%和5.71%（P＜0.05）,两组妊娠率分别为83.33%和81.25%,分娩率分别为83.33%和81.25%,均无统计学意义（P＞0.05）.结论 保守手术和辅助化疗对有生育要求的MOGCT患者是安全、有效的,在不影响存活率的前提下,对月经和生育功能无影响.     

卵巢恶性生殖细胞肿瘤预后及生育状况分析

目的:探讨卵巢恶性生殖细胞肿瘤(MOGCTs)的临床特点、5年累积生存率以及行保留生育功能手术及化疗后患者的月经及生育状况。方法:采用回顾性分析法对我院1999年5月至2009年10月收治的34例MOGCTs患者的临床资料进行分析。结果:患者发病中位年龄28.5岁,34例患者中行根治性手术13例,行保留生育功能手术21例。单纯无性细胞瘤7例,非无性细胞瘤27例。26例患者术后补充化疗,其中行保留生育功能手术并化疗18例。化疗以博来霉素+依托泊苷+顺铂方案(BEP方案)及顺铂+长春新碱+博来霉素方案(PVB方案)为主。共随访9～146月,平均随访53.7±37.3月,失访4例,死亡3例,5年累积生存率为89%。临床观察指标中仅组织学分级为Ⅰ级的患者5年累积生存率(100%)高于Ⅱ～Ⅲ级(73%),差异有统计学意义(P=0.02),而各种手术类型、手术病理不同分期和不同组织学类型间的比较,差异均无统计学意义(P>0.05)。18例保留生育功能患者化疗后,月经异常发生率为83.3%(15/18),化疗结束后2～4月开始逐渐恢复。有生育计划的6例患者,共获得妊娠4例,其中3例自然妊娠,1例助孕后妊娠,共娩出健康新生儿3例。结论:MOGCTs总体预后较好,PVB、BEP方案是有效的化疗方案,化疗对行保留生育功能治疗患者卵巢功能的影响是可逆的,对于有生育要求的患者可行保留生育功能治疗并获得满意妊娠。     

术后化疗对卵巢恶性肿瘤患者的卵巢功能损伤的临床分析

目的　探讨恶性卵巢肿瘤保留生育功能手术的术后化疗对卵巢功能及胎儿的影响。方法　回顾性分析日本独协医科大学 1 990年 1月～ 1 998年 1月间收治的 9例保留生育功能手术、术后化疗的恶性卵巢肿瘤患者的临床资料结果。结果　除 1例Ⅳ期卵巢无性细胞瘤死亡外 ,其余 8例均健在 ,存活时间为 2年 1 0个月～1 1年 2个月。结婚 5例中有 4例已经妊娠分娩 ,健康婴儿 6人 ,自然流产 1例 ,人工流产 1例。 9例患者中 6例月经正常 ,其中 5例基础体温呈双相 ,黄体生成激素 (LH)、卵泡刺激素 (FSH)值均正常 ,1例化疗期间月经初潮 ;3例LH ,FSH值升高出现停经 ,分别于化疗后 2、 4、 1 2个月恢复月经来朝 ,LH ,FSH值恢复正常 ,基础体温呈双相。结论　在早期恶性卵巢肿瘤特别是卵巢生殖细胞恶性肿瘤 (包括晚期 )的手术治疗中 ,保留生育功能的手术并辅以术后化疗 ,疗效肯定 ;化疗对卵巢功能的损伤是可逆的 ,对胎儿一般无致畸作用     

111例卵巢恶性生殖细胞肿瘤的临床特征及预后分析

目的:探讨卵巢恶性生殖细胞肿瘤的临床特征与预后的关系,为临床研究和治疗提供参考依据。方法:回顾分析我院2003年1月至12月收治的111例卵巢恶性生殖细胞肿瘤的临床资料。分析患者的发病年龄、病理类型、手术病理分期、手术方式、肿瘤标记物高低、术后化疗疗程等因素对患者预后的影响及化疗对月经生育状况的影响。结果:本组患者中位发病年龄22岁,平均(21.43±12.92)岁。患者均行手术治疗。99例在初次手术中保留了生育功能,95例接受了术后补充化疗,1~8个疗程。平均随访时间78.0个月,失访3例。3年生存率98.1%(106/108),5年生存率94.7%(71/75)。不同病理分期、肿瘤类型的5年生存率比较,差异有统计学意义(P0.05);不同病理分期、化疗疗程的总生存率比较,差异有统计学意义(P0.05)。23例化疗前月经规律的患者于化疗第2~3个疗程开始出现月经异常现象,均于化疗结束3~5月恢复正常。31例患者成功自然妊娠并分娩,31例新生儿均体健。结论:卵巢恶性生殖细胞肿瘤患者的总生存率与手术-病理分期及化疗疗程有关,化疗对卵巢功能和生育无明显影响。     

30岁以下卵巢肿瘤患者223例临床分析

目的:探讨年龄30岁以下卵巢肿瘤患者的临床特点、病理类型、治疗及预后.方法:回顾性分析1992年10月一2007年10月间、年龄30岁以下223例卵巢肿瘤患者的临床资料.结果:有明显临床症状就诊者占71.30%(168/223).良性肿瘤192例(86.10%),恶性肿瘤包括低度恶性潜能上皮性肿瘤(L,MP)31例(13.90%).生殖细胞肿瘤91例、上皮性肿瘤72例、性索间质肿瘤9例、卵巢瘤样病变5l例.良性肿瘤中蒂扭转者切除卵巢的比例高于非蒂扭转者.恶性肿瘤手术病理分期:I期28例、Ⅱ期l例、Ⅲ期2例,其中22例保留生育功能.11例LMP患者术后未化疗,其余20例恶性肿瘤患者中19例进行化疗.随访时间10～181个月,27例无瘤生存,4例死亡;21例月经正常,9例有生育计划的患者中.7次妊娠.4次足月分娩.总5年生存率为80.2l%,病理分期是影响生存率的主要因素.结论:30岁以下年轻患者卵巢肿瘤以良性、生殖细胞肿瘤为主.卵巢恶性肿瘤临床手术病理分期早期,手术应尽可能保留生育功能.化疗对卵巢及生育功能无明显影响.应重视年轻女性的临床表现并定期妇科检查.     

卵巢恶性肿瘤保留生育功能后化疗的策略及卵巢保护

正卵巢恶性肿瘤的发病年龄呈现年轻化趋势,随着医学手术技巧的提高和医学理念的转变,越来越多的年轻卵巢恶性肿瘤患者,接受保留生育功能的手术治疗。这些患者大部分在术后需要进一步化疗作为辅助治疗。本文从卵巢恶性肿瘤保留生育功能术后化疗的指征、方案、疗程及卵巢保护措施等方面的最新进展进行讨论。     

卵巢恶性肿瘤患者保留生育功能手术的指征及处理原则

年轻的卵巢恶性肿瘤患者施行保留生育功能手术应限于早期且组织学类型较好者,如高、中分化上皮性肿瘤而非透明细胞瘤。术后一般不影响预后,且妊娠结局良好。而对中、晚期患者一般不推荐施行保留生育功能手术。卵巢交界性肿瘤患者年龄相对较轻,而且在诊断时多为Ⅰ期肿瘤,施行保留生育功能手术后妊娠成功率甚高。对卵巢交界性肿瘤患者甚至可行卵巢囊肿剥除术,其并不影响预后。生殖细胞肿瘤患者行保留生育功能手术的文献报道多为无性细胞瘤,手术成功率较高。而对晚期或其他类型生殖细胞肿瘤患者也有尝试保留生育功能手术,但这仅为个案报道,通常并不推荐施行保留生育功能手术,除非患者及家属有强烈意愿。对于施行保留生育功能手术的卵巢恶性肿瘤患者,由于具体情况不同,手术应因人而异行个体化治疗。     

30岁以下卵巢肿瘤患者223例临床分析

目的：探讨年龄30岁以下卵巢肿瘤患者的临床特点、病理类型、治疗及预后。方法：回顾性分析1992年10月-2007年10月间、年龄30岁以下223例卵巢肿瘤患者的临床资料。结果：有明显临床症状就诊者占71.30％（168／223）。良性肿瘤192例（86．10％）,恶性肿瘤包括低度恶性潜能上皮性肿瘤（LMP）31例（13．90％）。生殖细胞肿瘤91例、上皮性肿瘤72例、性索间质肿瘤9例、卵巢瘤样病变51例。良性肿瘤中蒂扭转者切除卵巢的比例高于非蒂扭转者。恶性肿瘤手术病理分期：Ⅰ期28例、Ⅱ期1例、Ⅲ期2例,其中22例保留生育功能。11例LMP患者术后未化疗,其余20例恶性肿瘤患者中19例进行化疗。随访时间10～181个月,27例无瘤生存,4例死亡;21例月经正常,9例有生育计划的患者中,7次妊娠,4次足月分娩。总5年生存率为80．21％,病理分期是影响生存率的主要因素。结论：30岁以下年轻患者卵巢肿瘤以良性、生殖细胞肿瘤为主。卵巢恶性肿瘤临床手术病理分期早期,手术应尽可能保留生育功能。化疗对卵巢及生育功能无明显影响。应重视年轻女性的临床表现并定期妇科检查。     

Malignant germ cell tumors of the ovary

OBJECTIVE: To evaluate the efficacy of adjuvant therapy for ovarian germ cell tumors. METHODS: We reviewed records of women who had malignant germ cell tumors of the ovary from 1977-1997. RESULTS: Seventy-two women had surgical resections of malignant ovarian germ cell tumors and most received adjuvant therapy. Fifty-six women (78%) presented with stage I disease, and 16 (22%) had more advanced disease. Tumor subtypes included dysgerminoma (n = 20), yolk sac tumor (n = 8), immature teratoma (n = 29) and mixed germ cell tumor (n = 15). Surgical management of the 56 with stage I disease consisted of total abdominal hysterectomy, bilateral salpingo-oophorectomy, and extensive surgical staging in ten women, whereas a conservative surgical approach, consisting of unilateral adnexectomy with or without comprehensive surgical staging, was adopted in later years (n = 46). Fifty-six women were treated with postoperative chemotherapy, predominantly platinum-based regimens. The 5-year actuarial survival rate was 93%. None of the 36 women who presented after 1984 have died of disease. CONCLUSION: These data confirmed that platinum-based adjuvant treatments allow most women with ovarian germ cell malignancies to have conservative surgery without compromising survival.     

外阴恶性肿瘤79例临床治疗方法及预后分析

目的:探讨外阴恶性肿瘤不同治疗方法的临床效果及预后。方法:对2000年1月至2010年6月本院收治的79例外阴恶性肿瘤的治疗及预后进行回顾性研究。结果:Ⅰ、Ⅱ、Ⅲ、Ⅳ期的3年、5年生存率比较差异均有统计学意义(P<0.05);部分性外阴根治术组与传统全外阴根治术组3年、5年生存率比较差异无统计学意义(P>0.05);外阴癌根治术加放疗与单纯放疗5年生存率比较差异有高度统计学意义及统计学意义(P<0.05);腹股沟淋巴结阴性患者的5年生存率与阳性患者比较及盆腔淋巴结阴性患者的5年生存率与阳性患者比较差异有高度统计学意义及统计学意义(P<0.01,P<0.05)。结论:临床分期及淋巴结转移状况是对外阴恶性肿瘤的预后具有显著影响的两个因素。外阴恶性肿瘤的治疗方式应具个体化。     

Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy

OBJECTIVES: The purpose of this study was to determine the recurrence rate, survival, and pregnancy outcome in patients with Stage IA and Stage IC invasive epithelial ovarian cancer treated with unilateral adnexectomy. METHODS: A multi-institutional retrospective investigation was undertaken to identify patients with Stage IA and IC epithelial ovarian cancer who were treated with fertility-sparing surgery. All patients with ovarian tumors of borderline malignancy were excluded. Long-term follow-up was obtained through tumor registries and telephone interviews. The time and sites of tumor recurrence, patient survival, and pregnancy outcomes were recorded for every patient. RESULTS: Fifty two patients with Stage I epithelial ovarian cancer treated from 1965 to 2000 at 8 participating institutions were identified. Forty-two patients had Stage IA disease, and 10 had Stage IC cancers. Cell type was distributed as follows: mucinous, 25; serous, 10; endometrioid, 10; clear cell, 5; and mixed, 2. Histologic differentiation was as follows: grade 1, 38; grade 2, 9; and grade 3, 5. Twenty patients received adjuvant chemotherapy (mean 6 courses, range 3-12 courses). Patients received the following chemotherapeutic agents: cisplatin/taxol or carboplatin/taxol, 11; melphalan, 5; cisplatin and cyclophosphamide, 3; and single-agent cisplatin, 1. Eight patients had second-look laparotomies and all were negative. Duration of follow-up ranged from 6 to 426 months (median 68 months). Five patients developed tumor recurrence 8-78 months after initial surgery. Sites of recurrence were as follows: contralateral ovary, 3; peritoneum, 1; and lung, 1. Nine patients underwent subsequent hysterectomy and contralateral oophorectomy for benign disease. At present, 50 patients are alive without evidence of disease and 2 have died of disease 13 and 97 months after initial treatment. The estimated survival was 98% at 5 years and 93% at 10 years.Twenty-four patients attempted pregnancy and 17 (71%) conceived. These 17 patients had 26 term deliveries (no congenital anomalies noted) and 5 spontaneous abortions. CONCLUSION: The long-term survival of patients with Stage IA and IC epithelial ovarian cancer treated with unilateral adnexectomy is excellent. Fertility-sparing surgery should be considered as a treatment option in women with Stage I epithelial ovarian cancer who desire further childbearing.     

Anti-Müllerian hormone as a marker of ovarian reserve in patients with ovarian malignancies who have undergone fertility-preserving surgery and chemotherapy

Abstract

With proper and careful selection of patients, fertility-preserving surgery may be feasible in patients with ovarian malignancies. However, the loss of follicles by oophorectomy and chemotherapy results in decreased ovarian reserve, which consecutively affects reproductive capacity. We evaluated postoperative levels of serum anti-Müllerian hormone (AMH) in women with ovarian malignancies to assess the impact of the fertility-preserving surgery with or without the administration of chemotherapy on ovarian reserve. In 13 patients who underwent the fertility-preserving surgery with (n?=?9) or without (n?=?4) the administration of chemotherapy, serum AMH levels were measured and compared with serum AMH levels measured in patients undergone cystectomy for benign ovarian tumors as a control. We found that the mean AMH level in the treatment group measured 0.9?ng/mL, which was significantly lower than that measured in the control group (4.70?±?3.77?ng/mL). The possibility of decreased ovarian reserve occurring in patients with ovarian malignancies following treatment with fertility-preserving surgery with or without the administration of chemotherapy should be considered for fertility planning.     

Successful pregnancy after conservative surgery and chemotherapy for dysgerminoma of the ovary: case report]

OBJECTIVES: Considering the important improvement of surgical techniques and chemotherapy in the last few years, it is possible today, in selected cases of patients previously treated for ovarian cancer, to support their desire for motherhood, thus improving the quality of life for them. The major problem for the Gynecologic Oncologist in treating young women for ovarian tumor is the lack of statistically significant experience world-wide, because of the very few cases in which the reproductive function is preserved, and pregnancy is subsequently possible. STUDY DESIGN: The aim of this study was presentation the successful pregnancy after conservative surgery and chemotherapy for dysgerminoma of the ovary stage Ia. RESULTS: The patient age 23 was admitted to Department of Gynecology & Obstetric in Hospital of S?upsk in 1995 year with diagnosis right ovarian tumor. Right-side adnexectomy was performed initially. Histopathological examination of surgical specimen revelated dysgerminoma ovary stage Ia. Due to the clearly elevated tumor marker levels, indicating an involvement of other germ cell elements, and necrobiosis of tumor, we opted for postoperative chemotherapy instead of radiotherapy. Six cycles of BEP protocol chemotherapy was given. The follow-up included regular monitoring of the tumor markers. In the year 1998 the patient conceived and had a delivery of a normal infant at term. To date, there has been no indication towards tumor recurrence. CONCLUSION: After adequate staging and accurate information is given to the patient, conservative treatment may be safe in some women with early ovarian cancer. In early stage pure ovarian dysgerminoma conservative surgery combined with radiotherapy or chemotherapy showed high complete remission rates and excellent survival rates. For younger patients and those with gestation desires as well as patients with advanced diseases, adjuvant chemotherapy following surgery might be a better choice.     

卵巢交界性肿瘤手术治疗的预后相关因素分析

目的:探讨卵巢交界性肿瘤(BOTs)患者手术治疗后影响复发率及妊娠结局的相关因素。方法:收集郑州大学第三附属医院2010年3月至2018年12月手术治疗的96例BOTs患者的病例资料及随访结果,行回顾性统计学分析。结果:单因素分析显示患者术前CA199水平、手术途径、手术范围、肿瘤直径、国际妇产科联盟(FIGO)分期与BOTs手术治疗后复发有关(P<0.05),但多因素Logistic回归分析结果显示以上因素均不是肿瘤复发的独立危险因素。保守性手术组的手术时间、术中失血量均低于根治性手术组(P<0.05),且复发率高于根治性手术组(16.1%vs 0,P<0.05)。根治性手术组、单侧附件切除术组及肿瘤剥除术组3组术后复发率分别为0、12.5%、18.2%,差异有统计学意义(P<0.05)。腹腔镜组患者的无瘤生存期(DFS)明显高于开腹组(63.7月vs 50.9月),复发率低于开腹组(4.6%vs 25.6%),差异有统计学意义(P<0.05)。在保留生育功能患者中,15例(39.4%)患者成功妊娠,但肿瘤剥除术组与单侧附件切除术组之间以及腹腔镜手术组与开腹手术组之间妊娠率差异无统计学意义(P>0.05)。结论:术前CA199水平、FIGO分期、肿瘤直径及手术途径、手术范围可能与BOTs术后复发有关,但均不是肿瘤复发的独立危险因素。相对于保守性手术,根治性手术的患者的术后复发率更低,但对于有生育需求的年轻患者可行保留生育能力手术,但术后需严密随访。     

Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors

OBJECTIVE: To assess clinical outcome and fertility in patients treated conservatively for a low malignant potential (LMP) ovarian tumor. DESIGN: Retrospective study. SETTING: Gynecologic oncology department of a cancer care center in France. PATIENT(S): Forty-four patients treated with conservative management for a stage I (n = 32) or stage II or III (n = 12) LMP tumor. INTERVENTION(S): Thirty-three patients had unilateral adnexectomy and 11 had cystectomy. Cystectomy was bilateral in 1 patient and was done in conjunction with contralateral adnexectomy in 5 patients. MAIN OUTCOME MEASURE(S): Tumor recurrence and pregnancy rates. RESULT(S): Tumor recurrence rates after radical surgery (hysterectomy with bilateral salpingo-oophorectomy), adnexectomy, and cystectomy were 5.7%, 15.1%, and 36.3%, respectively (P<.01). Among patients who initially received conservative treatment, tumors did not recur in the form of invasive carcinoma. Five patients who had recurrence underwent repeated conservative management; these patients are alive and free of disease. Seventeen pregnancies (of which 15 were spontaneous) occurred in 14 patients; 13 pregnancies occurred in patients with stage I disease and 4 occurred in patients with stage III disease. CONCLUSION(S): Conservative management of LMP tumor significantly increases the risk of recurrence but does not affect overall survival. Such management offers even patients with advanced disease the chance to have spontaneous pregnancy. Conservative management might be proposed in young patients who wish to preserve their fertility, but careful follow-up will be required to detect tumor recurrence.     

Prognosis and fertility after conservative treatment for ovarian tumors of limited malignity: review of 68 cases

The aim of this retrospective study was to evaluate the rate of recurrence and the reproductive outcome after surgical conservative treatment of low malignant ovarian tumors (LMOT). MATERIAL AND METHODS: Sixty-eight patients with 50 Stage I LMOT and 18 LMOT with peritoneal implants treated conservatively at institut Gustave-Roussy, between January 1969 and December 2000. Fifty-nine patients had an unilateral adnexectomy (associated twelve times with a contralateral cystectomy), Seven had a bilateral cystectomy and two an unilateral cystectomy. Five patients received adjuvant therapy. RESULTS: With a median follow-up of 71.5 months, 16 patients recurred and one had evolutive peritoneal disease. The histologic pattern of ovarian recurrences was always of borderline type. The histologic patterns of peritoneal recurrence was similar to those initially diagnosed except in one case. Peritoneal implants, exophytic tumor and serous type tumor were significatively associated with a higher 5-year recurrence rate. Recurrence was more frequent after cystectomy than unilateral adnexectomy (p = 0.13). None of patients treated conservatively recurred under the form of ovarian carcinoma. None patient died of tumor. Nineteen patients experienced 26 pregnancies: 24 were spontaneous in a median delay of 19 months. Seven infertile patients underwent ovarian stimulation. None recurred after infertility treatments. The 2-year and 5-year cumulative pregnancy rate were respectively 41.9% and 59.8%. Four patients experienced a pregnancy after a conservative treatment of their recurrence. CONCLUSION: Despite a high recurrence rate, especially in stage II and III serous LMOT, conservative treatment of LMOT does not affect survival and should be considered in young patients. Such treatment is not advised in case of invasive peritoneal implants. Spontaneous pregnancy rate is good but the frequent infertility associated with these tumors can afterwards require ovarian stimulation. Limited number of stimulation cycles is acceptable in such patients.